DDInter1965 DDInter922
Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. Although it has been nasally administered for treating the common cold, this route of administration has been associated with some cases of anosmia,,,. Studies show that zinc may be better absorbed in humans in the gluconate form,, however, results from other studies may vary.[A27280, L2082] Interestingly, zinc supplementation has become a critical intervention for treating diarrheal episodes in children. Studies suggest that administration of zinc along with new low osmolarity oral rehydration solutions/salts (oral rehydration solution), may reduce both the duration and severity of diarrhe
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mycophenolic acid
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Satralizumab
Zinc gluconate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gatifloxacin
Zinc gluconate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baloxavir marboxil
Zinc gluconate {u} may lead to a major life threatening interaction when taken with {v} Raltegravir
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil
Zinc gluconate may lead to a major life threatening interaction when taken with Raltegravir